Dispatch From J.P. Morgan: Wall Street Sells Celgene As It Raises Long-Term Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Investors had been expecting a big wow from Celgene when it raised guidance over various periods out to 2017. The market got about what it expected, but nothing more.